Cagent Secures Funding to Expand Angioplasty Technology

Cagent Vascular Raises over $30 Million in Series C Financing Round to Accelerate US Market Expansion

Cagent Vascular, a leading medical device company focusing on the treatment of peripheral artery disease (PAD) and chronic limb-threatening ischemia (CLTI), has successfully closed a series C financing round, raising more than $30 million. The funds will be used to expedite the adoption of their innovative Serration Angioplasty Technology and expand their product portfolio.